Hospital for Special Surgery account plan
Top-ranked orthopedic and rheumatology
At a glance
Hospital for Special Surgery (HSS) is a New York not-for-profit orthopedic and rheumatology hospital with $2,050.1 million of operating revenue in 2025.
Hospital for Special Surgery (HSS) is a not-for-profit academic hospital in Manhattan specialised in musculoskeletal care, orthopedic surgery and rheumatology, with research and graduate medical education. It performs 46,000 surgeries a year and sees more than 500,000 patients a year, and serves as the principal orthopedic and rheumatology facility for New York Presbyterian Hospital. In 2025 total operating revenue was $2,050.1 million (2024: $1,851.4 million) and the operating surplus before other items $141.2 million, with commercial payors providing $1,372.4 million of net patient service revenue. It is a Section 501(c)(3) organisation and expands through physician co-owned ambulatory surgery centers and regional collaborations.
Business units
The Hospital (main campus, Manhattan)
about 68% of 2025 operating expenses (computed; healthcare services $1,291.1 million)Specialised inpatient and outpatient orthopedic and rheumatology care, billed mostly to commercial payors. The 12-story Kellen Tower, with inpatient beds, physician offices and radiology, opened in early 2026.
Ambulatory surgery centers
Majority-owned ASCs in Manhattan, the West Side, Long Island and Mahwah, co-owned with HSS physicians, plus the HSS ASC Development Network. In October 2025 HSS and General Atlantic acquired Legent Health to launch an independently operated national orthopedic and spine ASC platform.
Physician practices and regional collaborations
Wholly owned practices including TJA Orthopedic Surgery, P.C. and HSS-Florida Physicians, the management of Stamford Hospital's orthopedic department in Connecticut since 2016, and from March 2026 a collaboration with Jupiter Medical Center in Palm Beach County, Florida.
Research
about 3% of 2025 operating expenses (computed; $62.4 million)Basic, translational and clinical research in musculoskeletal diseases, with federal award expenditures of $20.1 million in 2025, mostly from the Department of Health and Human Services.
Education
Education in musculoskeletal medicine for physicians and allied health professionals, reported as $71.3 million of community benefit in 2025; the HSS orthopedics department is the Department of Orthopedics at Weill Cornell Medicine.
The Hospital for Special Surgery Fund and affiliates
The fundraising and holding side, including HSS Properties Corporation for real estate and the Cayman captive insurer MIAC. From January 1, 2026 the Hospital is the Fund's sole corporate member.
Strategic priorities
- National outpatient orthopedic platform
- With General Atlantic, HSS acquired Legent Health in October 2025 to take its orthopedic and spine model nationwide through ASCs, applying its standardised clinical care pathways.
- Shift to outpatient surgery
- CEO Bryan Kelly says close to 80% of orthopedics is now authorised for payment as outpatient surgery, versus roughly half before COVID-19, and HSS had built or planned at least seven ASCs before the Legent deal.
- Regional expansion
- Beyond the main campus, HSS works through the Stamford Hospital collaboration and, from March 2026, a collaboration with Jupiter Medical Center in Florida.
- Agentic AI and digital care models
- Chief Digital and Technology Officer Ashis Barad aims to use AI to create new care models, starting with call-center triage, appointment scheduling, post-surgery check-ins and HR policy look-ups.
- Data, outcomes and payer value
- HSS cites mature clinical protocols and outcome data, and sees standardised orthopedic data as valuable to payer partners.
Investments and deals
- Kellen Tower
- The 12-story tower was substantially complete at December 31, 2025 and opened in early 2026; additions to property, plant and equipment were $133.4 million in 2025.
- Legent Health acquisition
- In October 2025 HSS partnered with General Atlantic to acquire Plano, Texas-based Legent Health, launching a national ASC platform.
- ASC financing
- In 2025 HSS Long Island ASC took a construction loan of up to $27.6 million and HSS Mahwah ASC borrowed $10.6 million, both guaranteed by the Hospital.
- New leases
- Operating lease liabilities rose to $641.8 million from $447.2 million after $210.6 million of new leases in 2025.
- Implant lab and gait analysis
- An in-house implant lab partners with a company to 3-D print custom implants, and markerless computer-vision gait analysis is used in joint replacement research.
Challenges and risks
- Inpatient surgery economics
- Kelly says the economics of inpatient surgery are becoming more challenging "Because the cost is outpacing the revenue".
- Payment policy risk
- The statements warn that federal and state legislation could reduce payment and enrollment rates, and Medicare cost reports are settled only through 2022.
- Rising labour and supply costs
- Salaries and wages rose to $896.9 million in 2025 from $835.1 million, and supplies and other to $664.3 million from $613.8 million.
- Keeping quality while scaling
- Dr. Michael Ast warns against a cost-cutting "race to the bottom" that would affect quality of care as the ASC model expands.
- Investment and liability estimates
- The statements flag valuation uncertainty on $541.7 million of alternative investments and estimates of $135.2 million of captive insurance liabilities.
What leadership says
“This is an opportunity for us to expand HSS quality care to more patients in more locations at greater convenience and greater value.”
“High-quality care starts with high-quality doctors.”
“I believe agentic AI is going to be the great orchestrator of healthcare.”
“I look mostly at platform companies over point solutions”
Where a supplier can help
- AI agents for patient access
- Tied to the agentic AI priority, platforms for call-center triage, scheduling and post-surgery check-ins match the use cases HSS names; it prefers platforms over point solutions with proven ROI or outcome value.
- ASC rollout services
- The national ASC platform and new centers on Long Island and in Mahwah create needs for surgical equipment, facility build-out and ambulatory operations software.
- Outcomes data and payer analytics
- HSS's goal of standardising orthopedic data across sites for payer partners points to data integration and analytics suppliers.
- Cost control in a high-cost model
- Rising labour and supply costs and challenging inpatient economics make supply-chain, workforce and revenue-cycle efficiency offers relevant.
- Device and imaging innovation
- The implant lab, gait analysis and the emerging technologies committee that reviews every vendor are entry points for 3-D printing, robotics and computer-vision suppliers.
Tamtam's reading of the priorities and challenges above, not the company's own words.
Selling to companies like Hospital for Special Surgery?
Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.
Find similar companiesKey documents
Read in full by Tamtam; each summary links to the document itself.
- New York Society for the Relief of the Ruptured and Crippled, Maintaining the Hospital for Special Surgery and Affiliates: combined financial statements, supplementary information and Uniform Guidance audit reports, year ended December 31, 2025
- Hospital for Special Surgery (HSS) is a New York not-for-profit academic hospital whose stated mission is patient care, mobility and the advancement of orthopedic surgery, rheumatology and related fields through research and education; FY2025 statements (year to December 31, 2025) are, for the first time, combined for the Hospital and The Hospital for Special Surgery Fund (the "Enterprise"), audited by Ernst & Young with an unmodified opinion.
- Total operating revenue rose to $2,050.1 million in 2025 from $1,851.4 million in 2024; net patient service revenue was $1,768.2 million (2024: $1,605.7 million).
- Operating surplus before other items reached $141.2 million (2024: $83.3 million); excess of revenue over expenses was $173.5 million (2024: $137.9 million). Total operating expenses were $1,908.9 million, of which salaries and wages $896.9 million and supplies and other $664.3 million.
- Payor mix is overwhelmingly commercial: $1,372.4 million of net patient service revenue came from commercial payors, $297.6 million from Medicare and Medicare managed care, $40.7 million from international patients, $19.7 million from Medicaid.
- Balance sheet: total assets $4,120.3 million, total net assets $2,389.5 million, long-term debt (net of current portion) $554.7 million, mainly the taxable Series 2018 ($179.2 million) and Series 2020 ($350.0 million) bonds; $200.0 million of undrawn bank lines; $1.5 billion of financial assets available within one year.
- Capacity build-out: additions to property, plant and equipment of $133.4 million in 2025; the 12-story Kellen Tower (inpatient beds, physician offices, radiology) was substantially complete at year-end and opened in early 2026; operating lease liabilities jumped to $641.8 million from $447.2 million on $210.6 million of new leases.
- Growth beyond the main campus runs through majority-owned ambulatory surgery centers (Manhattan, West Side, Long Island, Mahwah) co-owned with HSS physicians, the Stamford Hospital collaboration (HSS Orthopedics at Stamford Hospital and at Tully) and, from March 2026, a collaboration with Jupiter Medical Center in Palm Beach County, Florida.
- Governance and organisation changes: a legal restructuring effective January 1, 2026 makes the Hospital the sole corporate member of the Fund and the shareholder of its Cayman captive insurer MIAC; the defined benefit pension plan was frozen to all accruals effective December 31, 2025.
- Community benefit totalled $277.7 million in 2025 (including $93.7 million of unreimbursed Medicare cost and $71.3 million for health professions education); federal award expenditures were $20.1 million, mostly Department of Health and Human Services research awards for arthritis and musculoskeletal and infectious diseases.
- Risks named: reliance on complex Medicare/Medicaid rules and possible federal and state payment cuts, open cost-report years, valuation uncertainty of $541.7 million of alternative investments, and professional liability claims ($135.2 million of captive insurance liabilities).
- Inside Hospital for Special Surgery's High-Stakes Bet to Take Its Orthopedic Model Nationwide (ASC News interview with CEO Dr. Bryan Kelly and Dr. Michael Ast)
- CEO Dr. Bryan Kelly, a surgeon at HSS since 1996 who still operates about a day and a half a week, frames the strategy as protecting and extending clinical excellence and "elevating the quality of musculoskeletal care across the country".
- In October 2025 HSS partnered with growth investor General Atlantic to acquire Plano, Texas-based Legent Health, launching an independently operated national platform of orthopedic and spine ambulatory surgery centers (ASCs).
- The rationale is the outpatient shift: Kelly says close to 80% of orthopedics is now authorised for payment as outpatient surgery, versus roughly half before COVID-19.
- Kelly: "The economics of inpatient surgery have become, and will become increasingly so, more and more challenging ... Because the cost is outpacing the revenue".
- HSS had built or planned at least seven ASCs (tri-state area and Florida) before the deal; it looked at "dozens" of possible platforms before choosing Legent, which accepted HSS's standardised clinical care pathways.
- The model is surgeon co-ownership and data: Kelly cites mature clinical protocols and outcome data; Dr. Michael Ast (chief medical innovation officer, director of ASC strategy) sees standardised orthopedic data as valuable to payer partners and warns against a cost-cutting "race to the bottom".
- Scale cited: No. 1 orthopedic hospital for 16 consecutive years, more than 2,000 alumni, 46,000 surgeries a year and more than 500,000 patients a year.
- Hospital for Special Surgery's Ashis Barad says AI must solve real problems (MedTech Dive interview)
- Ashis Barad, a pediatric gastroenterologist, joined HSS about a year before the interview as its first chief digital and technology officer, hired amid the new CEO's push to prioritise data and technology; he previously led digital efforts at Allegheny Health Network and Baylor Scott & White Health.
- His main theme: "I believe agentic AI is going to be the great orchestrator of healthcare" - AI should create new care models, not only efficiency.
- HSS wants to move "into the movement arena", an ecosystem from prevention, regenerative and performance care to wellness, longevity, surgical and non-surgical care, scaling "what is special in the Upper East Side of New York" to the U.S. and the world.
- Near-term AI agents: call-center triage, appointment scheduling, post-surgery check-ins and HR policy look-ups; complex multi-agent orchestration will "take years" and must be architected through data.
- Device-side work: an in-house implant lab partnering with a company to 3-D print custom implants, and markerless computer-vision gait analysis in the joint replacement service's research.
- Buying criteria: platform companies over point solutions; a tool must solve front-line problems and show business or patient value (outcomes, safety, quality or financial ROI); an emerging technologies committee reviews every vendor.
- HSS is setting up data, AI and cybersecurity governance, plus ethics, regulatory and equity review of new tools.
Questions about Hospital for Special Surgery
What does Hospital for Special Surgery do?
HSS is a not-for-profit academic hospital in New York specialised in orthopedic surgery, rheumatology and musculoskeletal care, with research and medical education.
What is HSS's revenue?
Total operating revenue was $2,050.1 million in 2025, up from $1,851.4 million in 2024, with an operating surplus before other items of $141.2 million.
How large is HSS's clinical activity?
HSS performs 46,000 surgeries a year and sees more than 500,000 patients a year.
What is HSS's growth strategy?
HSS is extending its model beyond New York through ambulatory surgery centers, including a national platform launched with General Atlantic through the Legent Health acquisition, and regional collaborations in Connecticut and Florida.
Who leads HSS?
Dr. Bryan Kelly is President and CEO, and Ashis Barad is Chief Digital and Technology Officer.
Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)